Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 5
2015 11
2016 5
2017 6
2018 8
2019 11
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.
Haugh IM, Watson IT, Alan Menter M. Haugh IM, et al. Proc (Bayl Univ Med Cent). 2018 Sep 21;31(4):524-525. doi: 10.1080/08998280.2018.1480246. eCollection 2018 Oct. Proc (Bayl Univ Med Cent). 2018. PMID: 30949000 Free PMC article.
We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. ...Oclacitinib is not currently indicated for use in humans....
We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. ...O
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Banovic F, Tarigo J, Gordon H, Barber JP, Gogal RM Jr. Banovic F, et al. Vet Dermatol. 2019 Feb;30(1):17-e6. doi: 10.1111/vde.12698. Epub 2018 Nov 12. Vet Dermatol. 2019. PMID: 30417482
METHODS AND MATERIALS: Lymphocyte-enriched cells were incubated with or without the T-cell mitogen concanavalin A (Con A), oclacitinib (0.5, 1 or 10 μM), ciclosporin (200 ng/mL), Con A + oclacitinib 1 μM and Con A + ciclosporin. ...RESULTS: Ciclosporin and oclaci
METHODS AND MATERIALS: Lymphocyte-enriched cells were incubated with or without the T-cell mitogen concanavalin A (Con A), oclacitinib
Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, Stegemann MR. Cosgrove SB, et al. Vet Dermatol. 2015 Jun;26(3):171-9, e35. doi: 10.1111/vde.12194. Epub 2015 Feb 16. Vet Dermatol. 2015. PMID: 25688708 Clinical Trial.
ANIMALS: Two hundred and forty-seven client-owned dogs with allergic skin disease that had previously benefited from oclacitinib therapy. ...Dogs received 0.4-0.6 mg/kg oclacitinib twice a day for 14 days, then once a day for up to 630 days. Assessments were perform …
ANIMALS: Two hundred and forty-seven client-owned dogs with allergic skin disease that had previously benefited from oclacitinib ther …
A pharmacokinetic study of oclacitinib maleate in six cats.
Ferrer L, Carrasco I, Cristòfol C, Puigdemont A. Ferrer L, et al. Vet Dermatol. 2020 Apr;31(2):134-137. doi: 10.1111/vde.12819. Epub 2019 Nov 26. Vet Dermatol. 2020. PMID: 31769185
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. ...OBJECTIVE: To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous admin …
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic …
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Lopes NL, Campos DR, Machado MA, Alves MSR, de Souza MSG, da Veiga CCP, Merlo A, Scott FB, Fernandes JI. Lopes NL, et al. BMC Vet Res. 2019 May 8;15(1):137. doi: 10.1186/s12917-019-1893-x. BMC Vet Res. 2019. PMID: 31068210 Free PMC article. Clinical Trial.
BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this spe …
BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritu …
Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.
de Oliveira JK, Williams DL, Bollmann C, de Seabra NM, Bortolini M, Montiani-Ferreira F. de Oliveira JK, et al. Vet Ophthalmol. 2019 Sep;22(5):633-643. doi: 10.1111/vop.12634. Epub 2019 Feb 6. Vet Ophthalmol. 2019. PMID: 30724448
PROCEDURES: The animals were submitted to a randomized, open-label, 5-week study and divided into 3 treatment groups treated with the following ophthalmic solutions: (a) 0.1% oclacitinib, (b) 0.1% oclacitinib +0.01% tacrolimus, and (c) 0.01% tacrolimus. ...RESULTS: …
PROCEDURES: The animals were submitted to a randomized, open-label, 5-week study and divided into 3 treatment groups treated with the follow …
Oclacitinib depletes canine CD4(+) and CD8(+) T cells in vitro.
Jasiecka-Mikołajczyk A, Jaroszewski JJ, Maślanka T. Jasiecka-Mikołajczyk A, et al. Res Vet Sci. 2018 Dec;121:124-129. doi: 10.1016/j.rvsc.2018.10.014. Epub 2018 Oct 29. Res Vet Sci. 2018. PMID: 30391724
Oclacitinib (OCL) is a novel immunosuppressive agent approved for dogs that controls itch and inflammation in allergic disease via the inhibition of the JAK/STAT pathway. ...
Oclacitinib (OCL) is a novel immunosuppressive agent approved for dogs that controls itch and inflammation in allergic disease via th
Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Ortalda C, Noli C, Colombo S, Borio S. Ortalda C, et al. Vet Dermatol. 2015 Aug;26(4):235-e52. doi: 10.1111/vde.12218. Epub 2015 May 4. Vet Dermatol. 2015. PMID: 25940959
HYPOTHESIS/OBJECTIVES: To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis. ...CONCLUSIONS AND CLINICAL IMPORTANCE: Oclacitinib at 0.4-0.6 mg/kg p.o. may be an effective and …
HYPOTHESIS/OBJECTIVES: To evaluate the efficacy, ease of administration and tolerability of oclacitinib in feline nonflea-, nonfood-i …
The role of oclacitinib in the management of ischaemic dermatopathy in four dogs.
Levy BJ, Linder KE, Olivry T. Levy BJ, et al. Vet Dermatol. 2019 Jun;30(3):201-e63. doi: 10.1111/vde.12743. Epub 2019 Apr 21. Vet Dermatol. 2019. PMID: 31006925
Oclacitinib is a generally well-tolerated, veterinary-approved, nonselective JAKinib that has therapeutic potential as an immunosuppressant. ...Such observation warrants further studies of the safety, efficacy and mechanism of action of oclacitinib as an immunosuppr
Oclacitinib is a generally well-tolerated, veterinary-approved, nonselective JAKinib that has therapeutic potential as an immunosuppr
A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
Marsella R, Ahrens K. Marsella R, et al. Vet Dermatol. 2018 Oct;29(5):439-e146. doi: 10.1111/vde.12660. Epub 2018 Jun 21. Vet Dermatol. 2018. PMID: 29926994 Clinical Trial.
Oclacitinib significantly increased (P = 0.006) time to develop skin reactions compared to placebo. Four (of five) dogs receiving oclacitinib failed to develop skin reactions, whereas all placebo dogs developed dermatitis. ...Significantly higher values were detecte
Oclacitinib significantly increased (P = 0.006) time to develop skin reactions compared to placebo. Four (of five) dogs receiving
48 results
Jump to page
Feedback